Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
about
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision MedicineCell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progressionProspective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.Photodynamic quenched cathepsin activity based probes for cancer detection and macrophage targeted therapy.Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease.Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cellsExperience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer.Mechanical phenotyping of breast cancer using MEMS: a method to demarcate benign and cancerous breast tissuesCysteine peptidase and its inhibitor activity levels and vitamin E concentration in normal human serum and colorectal carcinomas.Protease nexin-1 expression is altered in human breast cancer.Stress-resistant Translation of Cathepsin L mRNA in Breast Cancer ProgressionDifferential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target.Cathepsin L targeting in cancer treatment.Development of a Novel Enzyme-Linked Immunosorbent Assay Targeting a Neo-Epitope Generated by Cathepsin-Mediated Turnover of Type III Collagen and Its Application in Chronic Obstructive Pulmonary Disease.Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX(®), clinicopathological markers and tumor cell dissemination in the blood and bone marrow.Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patientsPresent status of adjuvant chemotherapy for elderly breast cancer patients.Impact of proteolytic enzymes in colorectal cancer development and progression.Cathepsin D is up-regulated in inflammatory bowel disease macrophages.
P2860
Q28067626-A2CF8262-07A9-4ACB-9E10-3A223A835835Q28299475-15D8643E-8DA0-4AEF-B353-77B7CA3F483DQ30318419-30EA5D79-599E-465C-920A-B02D25E3CC38Q30411275-FD112DE3-0EC4-435E-8AD3-C251156A1C26Q33186595-E2C2BE3B-0E63-44B8-9451-B2E6C1E5938BQ33350682-CEAEEB9C-AC3F-4292-9358-07CC49C9521EQ33751184-C5EE7A81-1B93-4A5E-9F63-7A90DE24D637Q34095789-03D4F83A-08A3-4982-A777-0410A72B9E7BQ34471768-289CF696-0B19-44B5-BD1F-CD582EAD224BQ34604711-763956D9-19B8-4013-9514-47451ADCB16EQ34768102-BB98C8E3-8979-4F33-AF10-4F60FB829DC8Q35860710-65F4C0CD-8BB0-4D8D-BBCF-11E75B709952Q36087869-2913ECDE-74CE-4C0C-B76A-70AA21863A3DQ36218199-FC757B40-4283-4008-8319-00DD53C66C25Q36246370-21D0D91E-7346-40D0-911B-F2F7E7B9C2B5Q36557197-E755069E-88AA-4D4C-A469-74ECF13E6D69Q37560700-74F2C0A5-90F4-4006-881C-B0B88AC88BCCQ37671450-9FD1AADC-95BF-4C18-89BF-E6967C486BAEQ37677693-3A454061-AA4D-49E6-9F85-5FAABDBBA51DQ38259533-9390AD70-5333-4AA4-8F51-A11D578F85F4Q47927170-7926FC4D-62C2-4C67-BF50-DEE84CACAE80
P2860
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Prognostic impact of proteolyt ...... of adjuvant systemic therapy.
@en
Prognostic impact of proteolyt ...... of adjuvant systemic therapy.
@nl
type
label
Prognostic impact of proteolyt ...... of adjuvant systemic therapy.
@en
Prognostic impact of proteolyt ...... of adjuvant systemic therapy.
@nl
prefLabel
Prognostic impact of proteolyt ...... of adjuvant systemic therapy.
@en
Prognostic impact of proteolyt ...... of adjuvant systemic therapy.
@nl
P2093
P1476
Prognostic impact of proteolyt ...... s of adjuvant systemic therapy
@en
P2093
C Thomssen
P304
P407
P577
2001-09-01T00:00:00Z